Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models
Article in Scientific Reports (April 2024)
The most recent citing publications are shown below. View all 6 publications that cite this research output on Dimensions.
Article in Scientific Reports (April 2024)
Article in Frontiers in Immunology (January 2024)
Article in Frontiers in Surgery (September 2022)